OncoSec Medical Inc (ONCSQ)

[chickpea598]

I would think that Merck would be interested in increasing response rates to 48% if this included keytruda responders and also keytruda non-responders (broader patient base). I absolutely think going after the non-responder population is great but I also think that enhancing responders overall outcomes should not be discarded either. If I were on Keytruda and a doctor told me I am likely to have a 48% response with the addition of ep-il12 to my therapy as opposed to keytruda monotherapy at around 20-30% response rate I would opt for the combo therapy.

If Merck is only interested in pursuing the non-responder population with Oncosec then the point is mute right now.